These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 16000554)
1. Lysophosphatidic acid, a disintegrin and metalloprotease-17 and heparin-binding epidermal growth factor-like growth factor in ovarian cancer: the first word, not the last. Braun AH; Coffey RJ Clin Cancer Res; 2005 Jul; 11(13):4639-43. PubMed ID: 16000554 [No Abstract] [Full Text] [Related]
2. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Tanaka Y; Miyamoto S; Suzuki SO; Oki E; Yagi H; Sonoda K; Yamazaki A; Mizushima H; Maehara Y; Mekada E; Nakano H Clin Cancer Res; 2005 Jul; 11(13):4783-92. PubMed ID: 16000575 [TBL] [Abstract][Full Text] [Related]
3. Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy. Tsujioka H; Yotsumoto F; Hikita S; Ueda T; Kuroki M; Miyamoto S Curr Opin Obstet Gynecol; 2011 Feb; 23(1):24-30. PubMed ID: 20966750 [TBL] [Abstract][Full Text] [Related]
4. [HB-EGF is a promising target molecule for ovarian cancer]. Miyamoto S; Yagi H; Tanaka Y Fukuoka Igaku Zasshi; 2004 Nov; 95(11):286-90. PubMed ID: 15717494 [No Abstract] [Full Text] [Related]
5. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Miyamoto S; Hirata M; Yamazaki A; Kageyama T; Hasuwa H; Mizushima H; Tanaka Y; Yagi H; Sonoda K; Kai M; Kanoh H; Nakano H; Mekada E Cancer Res; 2004 Aug; 64(16):5720-7. PubMed ID: 15313912 [TBL] [Abstract][Full Text] [Related]
6. Heparin-binding epidermal growth factor-like growth factor as a new target molecule for cancer therapy. Miyamoto S; Yagi H; Yotsumoto F; Kawarabayashi T; Mekada E Adv Exp Med Biol; 2008; 622():281-95. PubMed ID: 18546636 [No Abstract] [Full Text] [Related]
8. [Membrane-anchored heparin-binding EGF-like growth factor processing by ADAM12 in cardiac hypertrophy]. Higashiyama S Nihon Rinsho; 2003 May; 61(5):767-75. PubMed ID: 12755001 [TBL] [Abstract][Full Text] [Related]
9. New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule. Miyamoto S; Yagi H; Yotsumoto F; Horiuchi S; Yoshizato T; Kawarabayashi T; Kuroki M; Mekada E Anticancer Res; 2007; 27(6A):3713-21. PubMed ID: 17970033 [TBL] [Abstract][Full Text] [Related]
10. Multimerisation of A disintegrin and metalloprotease protein-17 (ADAM17) is mediated by its EGF-like domain. Lorenzen I; Trad A; Grötzinger J Biochem Biophys Res Commun; 2011 Nov; 415(2):330-6. PubMed ID: 22033402 [TBL] [Abstract][Full Text] [Related]
11. Lysophosphatidic acid regulates murine blastocyst development by transactivation of receptors for heparin-binding EGF-like growth factor. Liu Z; Armant DR Exp Cell Res; 2004 Jun; 296(2):317-26. PubMed ID: 15149861 [TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor (EGF) receptor ligands in the chicken ovary: I. Evidence for heparin-binding EGF-like growth factor (HB-EGF) as a potential oocyte-derived signal to control granulosa cell proliferation and HB-EGF and kit ligand expression. Wang Y; Li J; Ying Wang C; Yan Kwok AH; Leung FC Endocrinology; 2007 Jul; 148(7):3426-40. PubMed ID: 17395697 [TBL] [Abstract][Full Text] [Related]
18. Lipid generation and signaling in ovarian cancer. Xu Y; Wang D; Wang Z Cancer Treat Res; 2009; 149():241-67. PubMed ID: 19763440 [No Abstract] [Full Text] [Related]
19. Lysophosphatidic acid and invasion. Wang F; Fishman DA Cancer Treat Res; 2009; 149():269-96. PubMed ID: 19763441 [No Abstract] [Full Text] [Related]
20. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. Gschwind A; Hart S; Fischer OM; Ullrich A EMBO J; 2003 May; 22(10):2411-21. PubMed ID: 12743035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]